• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AngioDynamics, Inc. - Common Stock (NQ:ANGO)

    11.58 +0.53 (+4.80%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,136,941
    Open 11.05
    Bid (Size) 10.20 (200)
    Ask (Size) 11.69 (100)
    Prev. Close 11.05
    Today's Range 11.05 - 11.62
    52wk Range 9.390 - 16.29
    Shares Outstanding 38,444,076
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript ↗
    Medtech segment surges 13.2% as NanoKnife prostate procedures hit record volumes. 
    Via The Motley Fool
    Topics Earnings World Trade

    Performance

    52-Week Range 28.9% below 52-week high
    11.58
    9.3952W Low 16.2952W High
    1 Week 16.1% below 1-week high
    10.621W Low 13.801W High

    AngioDynamics, Inc. - Common Stock (ANGO) traded between $9.39 and $16.29 over the past 52 weeks and last traded at $11.58, 28.9% below its 52-week high. Over the past week it ranged between $10.62 and $13.80.

    Past 12 Months
    +3.1%
    -25.3%
    -20.0%
    +12.0%
    -8.7%
    +1.5%
    1W +$0.35
    1M -$3.93
    3M -$2.89
    6M +$1.24
    YTD -$1.10
    1Y +$0.17

    ANGO was +1.5% over the past year, +12.0% over six months, -8.7% year to date, +3.1% in the last week.

    12 Months vs Market
    ANGO
    +1.5%
    DIA
    +12.6%
    SPY
    +16.5%
    QQQ
    +21.7%
    IWM
    +11.0%

    Over the past 12 months ANGO returned +1.5% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.5%, QQQ (Nasdaq 100) +21.7% and IWM (Russell 2000) +11.0%.

    Volume & Liquidity 1.87× 3-mo avg
    Today 1,136,941 3-mo avg 608.9K
    1W
    1.8M
    1M
    915.5K
    3M
    608.9K
    6M
    492.2K
    YTD
    519.1K
    1Y
    504.1K

    ANGO most recently traded 1,136,941 shares against a 3-month average daily volume of 608.9K.

    More News

    Read More
    News headline image
    Why AngioDynamics Crashed Today ↗
    Via The Motley Fool
    AngioDynamics (NASDAQ:ANGO) Posts Narrower Q1 Loss, Holds Guidance Below Consensus ↗
    Via Chartmill
    AngioDynamics (NASDAQ:ANGO) Surges on Strong Quarterly Beat as Med Tech Segment Drives Growth ↗
    Via Chartmill
    AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Thursday's session. ↗
    Via Chartmill
    News headline image
    AngioDynamics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027 ↗
    Via MarketBeat
    News headline image
    AngioDynamics to Participate in Upcoming Investor Conferences
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings World Trade
    News headline image
    AngioDynamics Q4 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Full Transcript: AngioDynamics Q4 2026 Earnings Call ↗
    Via Benzinga
    Topics Earnings
    News headline image
    AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
    From AngioDynamics, Inc.
    Via Business Wire
    News headline image
    Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability
    Via MarketMinute
    Topics Economy Retirement
    News headline image
    AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
    From AngioDynamics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is AngioDynamics, Inc. - Common Stock publicly traded?
    Yes, AngioDynamics, Inc. - Common Stock is publicly traded.
    What exchange does AngioDynamics, Inc. - Common Stock trade on?
    AngioDynamics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for AngioDynamics, Inc. - Common Stock?
    The ticker symbol for AngioDynamics, Inc. - Common Stock is ANGO on the Nasdaq Stock Market
    What is the current price of AngioDynamics, Inc. - Common Stock?
    The current price of AngioDynamics, Inc. - Common Stock is 11.58
    When was AngioDynamics, Inc. - Common Stock last traded?
    The last trade of AngioDynamics, Inc. - Common Stock was at 10/15/26 04:00 PM ET
    What is the market capitalization of AngioDynamics, Inc. - Common Stock?
    The market capitalization of AngioDynamics, Inc. - Common Stock is 445.18M
    How many shares of AngioDynamics, Inc. - Common Stock are outstanding?
    AngioDynamics, Inc. - Common Stock has 445M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.